An early MD Anderson trial found that IACS-6274, combined with bevacizumab and paclitaxel, shrank tumors in 9 of 13 women with measurable platinum-resistant ovarian cancer.
MD Anderson’s IACS-6274 Plus Two Standard Treatments Shrank Tumors in 9 of 13 Women With Resistant Ovarian Cancer
by | Nov 20, 2026 | Uncategorized | 0 comments

Recent Comments